Alison Birtle
Lancashire Teaching Hospitals NHS Foundation Trust
CancerInternal medicineUrologySurgeryOncologyRandomized controlled trialClinical endpointHazard ratioAbiraterone acetateEnzalutamideChemotherapyCisplatinCabazitaxelMEDLINEProstate cancerGemcitabineBladder cancerDocetaxelIn patientCastration resistantRadiation therapyClinical trialMedicine
Publications 140
#1John Staffurth (Cardiff University)H-Index: 34
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. Alison BirtleH-Index: 25
view all 20 authors...
Abstract null null Background null Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP). Evaluation of long-term patient-reported outcomes (PROs) is important to confirm safety and enhance patient information. null null null Objective null To determine whether 5-yr PROs from the CHHiP quality of life (QoL) substud...
#1Robert HuddartH-Index: 83
#2Shaista HafeezH-Index: 13
Last. Duncan B. McLarenH-Index: 13
view all 25 authors...
#1Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
#2Tibor CsősziH-Index: 10
Last. David I. QuinnH-Index: 72
view all 244 authors...
BACKGROUND PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma. METHODS KEYNOTE-361 is a randomised, open-label, phase 3 trial of patients aged at least 18 years, with untreated, locally advanced, unr...
10 CitationsSource
#1Robert Huddart (ICR: Institute of Cancer Research)H-Index: 83
#2Shaista Hafeez (ICR: Institute of Cancer Research)H-Index: 13
Last. Hybrid InvestigatorsH-Index: 1
view all 24 authors...
Purpose Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided radiation therapy delivery could improve outcomes by minimizing the volume of normal tissue irradiated. The HYBRID trial assessed the multicenter implementation, safety, and efficacy of this strategy. Methods HYBRID is a Phase II randomized trial that was conducted at 14 UK hospitals...
9 CitationsSource
#1Anders BjartellH-Index: 77
#2Nicolaas Lumen (Ghent University Hospital)H-Index: 29
Last. Simon Chowdhury (Guy's and St Thomas' NHS Foundation Trust)H-Index: 32
view all 16 authors...
BACKGROUND Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. Abiraterone acetate plus prednisone or prednisolone (AAP) prolongs survival in chemotherapy-naive and docetaxel-experienced patients. OBJECTIVE To evaluate the real-world safety and efficacy of AAP as first-line and second-line [po...
1 CitationsSource
#1Shalini Subramaniam (USYD: University of Sydney)H-Index: 1
#2Guy C. TonerH-Index: 25
Last. New Zealand UrogenitalH-Index: 2
view all 20 authors...
TPS390Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 is standard first-line chemotherapy for metastatic GCT categorised as intermediate risk or poor risk. Acceleration of ...
#1Alison BirtleH-Index: 25
#2John D. Chester (Cardiff University)H-Index: 30
Last. Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
view all 16 authors...
455Background: The POUT trial (CRUK/11/027; NCT01993979) previously reported (with median follow-up 30.3 months) that adjuvant chemotherapy improves disease free survival (DFS) for patients (pts) w...
3 CitationsSource
#1Robert JonesH-Index: 47
#2Amit Bahl (University Hospitals Bristol NHS Foundation Trust)H-Index: 24
Last. Simon J. Crabb (University of Southampton)H-Index: 30
view all 20 authors...
107Background: Saracatinib is an orally-available, highly selective inhibitor of Abl and Src family members. It is an ATP-competitive tyrosine kinase inhibitor. Preclinical data suggested that the ...
#1Simon J. CrabbH-Index: 30
#2Sarah Danson (Weston Park Hospital)H-Index: 31
Last. Gareth Griffiths (University of Southampton)H-Index: 30
view all 15 authors...
447Background: Pre-clinical data support a hypothesis that DNA methyltransferase inhibition will circumvent cisplatin resistance in various cancers including urothelial carcinoma (UC). SPIRE compri...
#1Benjamin W. Fischer-Valuck (Emory University)H-Index: 16
#2Jeff M. Michalski (WashU: Washington University in St. Louis)H-Index: 73
Last. Brian C. Baumann (UPenn: University of Pennsylvania)H-Index: 16
view all 19 authors...
Abstract: Introduction During the COVID-19 pandemic, providers and patients must engage in shared decision-making to ensure that the benefit of early intervention for muscle-invasive bladder cancer (MIBC) exceeds the risk of contracting COVID-19 in the clinic setting. It is unknown whether treatment delays for MIBC patients eligible for curative chemoradiation (CRT) compromise long-term outcomes. Patients and Methods In this study, we used the National Cancer Database to investigate if there is ...
2 CitationsSource